Drugs · acquisition-cost intelligence
Hyoscyamine ER
hyoscyamine sulfate· ingredient hyoscyamine· HYOSCYAMINE SULFATE .375 mg/1
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per EA
$0.49508
NADAC — pharmacy acquisition cost, not a retail/cash price
Acquisition-cost history
Weekly NADAC per EA — the trend nobody else shows. 6 weeks.
2025-12-172026-05-20
Same-ingredient options by acquisition cost
Other hyoscyamine products, cheapest acquisition cost first. Per EA — confirm strength/form equivalence before switching.
| Product | NADAC / EA | vs this |
|---|---|---|
| Hyoscyamine Sulfate ODT | $0.17222 | −$0.32290 |
| Digenyx | $0.17536 | −$0.31970 |
| Hyoscyamine Sulfate SL | $0.20161 | −$0.29350 |
| Uro-MP | $1.73 | +$1.23 |
| Me NaPhos MB Hyo 1 | $4.27 | +$3.78 |
Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.